{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:25:49Z","timestamp":1794288349967,"version":"4.9.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.wneu.2026.125356","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:31:31Z","timestamp":1790098291000},"page":"125356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Post-Treatment Performance Status and Prognosis in Patients with Brain Metastases as the First Manifestation of Advanced Nonsmall Cell Lung Cancer"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1021-7388","authenticated-orcid":false,"given":"Kenji","family":"Shoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Nishiwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3083-0964","authenticated-orcid":false,"given":"Noriyuki","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8778-2698","authenticated-orcid":false,"given":"Tsuyoshi","family":"Izumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2026.125356_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0305-7372(03)00105-1","article-title":"The management of brain metastases","volume":"29","author":"Patchell","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.wneu.2026.125356_bib2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10143-018-1013-6","article-title":"Neurosurgical management of patients with brain metastasis","volume":"43","author":"Hatiboglu","year":"2020","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.wneu.2026.125356_bib3","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/neuonc\/now127","article-title":"Updates in the management of brain metastases","volume":"18","author":"Arvold","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2026.125356_bib4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.wneu.2026.125356_bib5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejca.2020.03.006","article-title":"Systemic treatment of brain metastases in non-small cell lung cancer","volume":"132","author":"Page","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.wneu.2026.125356_bib6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ctrv.2017.02.004","article-title":"Management of brain metastasized non-small cell lung cancer (NSCLC) - from local treatment to new systemic therapies","volume":"54","author":"Tsakonas","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.wneu.2026.125356_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jocn.2020.08.006","article-title":"The primary sites leading to brain metastases: shifting trends at a tertiary care center","volume":"80","author":"Bhambhvani","year":"2020","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.wneu.2026.125356_bib8","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.wneu.2026.125356_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.14791\/btrt.2016.4.2.107","article-title":"Optimal treatment decision for brain metastases of unknown primary origin: the role and timing of radiosurgery","volume":"4","author":"Han","year":"2016","journal-title":"Brain Tumor Res Treat"},{"key":"10.1016\/j.wneu.2026.125356_bib10","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10585-018-9947-1","article-title":"Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center","volume":"35","author":"Fureder","year":"2018","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.wneu.2026.125356_bib11","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ijrobp.2014.07.002","article-title":"Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the Graded Prognostic Assessment (GPA)","volume":"90","author":"Sperduto","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.wneu.2026.125356_bib12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary report on the Graded Prognostic Assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases","volume":"30","author":"Sperduto","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.wneu.2026.125356_bib13","doi-asserted-by":"crossref","first-page":"8708","DOI":"10.3390\/ijms14058708","article-title":"Surgical resection of brain metastases impact on neurological outcome","volume":"14","author":"Sch\u00f6del","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.wneu.2026.125356_bib14","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(12)70211-5","article-title":"Global cancer transitions according to the human development index (2008-2030): a population-based study","volume":"13","author":"Bray","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2026.125356_bib15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jtho.2024.12.027","article-title":"A prospective phase II trial of first-line osimertinib for patients with EGFR mutation-positive NSCLC and poor performance status (OPEN\/TORG2040)","volume":"20","author":"Fukui","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.wneu.2026.125356_bib16","article-title":"Prognostic factors and impact of therapeutic intervention in patients with brain metastases at the initial presentation","volume":"16","author":"Ishikawa","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.wneu.2026.125356_bib17","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s10147-020-01687-w","article-title":"Survival outcomes following craniotomy for intracranial metastases from an unknown primary","volume":"25","author":"Gough","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.wneu.2026.125356_bib18","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s11060-022-04106-4","article-title":"Prognostic factors among patients with brain metastases from cancer of unknown primary site","volume":"159","author":"Sim\u00f5es","year":"2022","journal-title":"J Neurooncol"},{"key":"10.1016\/j.wneu.2026.125356_bib19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1025621819250","article-title":"Brain metastases in patients with cancer of unknown primary","volume":"64","author":"Bartelt","year":"2003","journal-title":"J Neurooncol"},{"key":"10.1016\/j.wneu.2026.125356_bib20","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/1097-0142(20000901)89:5<1095::AID-CNCR19>3.0.CO;2-H","article-title":"Brain metastases in patients with no known primary tumor","volume":"89","author":"Maesawa","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.wneu.2026.125356_bib21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3747\/co.25.4003","article-title":"Survival outcome differences based on treatments used and knowledge of the primary tumour site for patients with cancer of unknown and known primary in Ontario","volume":"25","author":"Kim","year":"2018","journal-title":"Curr Oncol"},{"key":"10.1016\/j.wneu.2026.125356_bib22","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.3171\/foc.2007.22.3.8","article-title":"Prognosis in patients presenting with brain metastasis from an undiagnosed primary tumor","volume":"22","author":"D'Ambrosio","year":"2007","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.wneu.2026.125356_bib23","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.20.01255","article-title":"Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient","volume":"38","author":"Sperduto","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.wneu.2026.125356_bib24","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ijrobp.2007.06.074","article-title":"A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database","volume":"70","author":"Sperduto","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.wneu.2026.125356_bib25","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1186\/s12885-024-12798-2","article-title":"Performance status improvement and advances in systemic treatment after brain metastases resection: a retrospective single-center cohort study of non-small cell lung cancer patients","volume":"24","author":"Hosoya","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.wneu.2026.125356_bib26","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2009.08.025","article-title":"Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients","volume":"77","author":"Sperduto","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.wneu.2026.125356_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10143-004-0364-3","article-title":"Surgical treatment for brain metastases: prognostic factors and survival in 177 patients","volume":"28","author":"Stark","year":"2005","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.wneu.2026.125356_bib28","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1002\/cam4.3402","article-title":"Surgical resection of symptomatic brain metastases improves the clinical status and facilitates further treatment","volume":"9","author":"Sch\u00f6del","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.wneu.2026.125356_bib29","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.lungcan.2013.08.016","article-title":"Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma","volume":"82","author":"Iuchi","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.wneu.2026.125356_bib30","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.2015.63.9443","article-title":"Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase \u2161 global study","volume":"34","author":"Ou","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.wneu.2026.125356_bib31","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3171\/2022.9.JNS221896","article-title":"Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone","volume":"138","author":"Dohm","year":"2023","journal-title":"J Neurosurg"},{"key":"10.1016\/j.wneu.2026.125356_bib32","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.wneu.2026.125356_bib33","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.3390\/cancers16193388","article-title":"Immune checkpoint inhibitors in the management of brain metastases from non-small cell lung cancer: a comprehensive review of current trials, guidelines and future directions","volume":"16","author":"Ranjan","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.wneu.2026.125356_bib34","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/neuonc\/noab129","article-title":"Immunotherapy in association with stereotactic radio-therapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO","volume":"23","author":"Scoccianti","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2026.125356_bib35","article-title":"Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis","volume":"148","author":"Vitale","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.wneu.2026.125356_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10555-026-10327-0","article-title":"Hyponatremia in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-014 meta-analysis","volume":"45","author":"Vitale","year":"2026","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.wneu.2026.125356_bib37","doi-asserted-by":"crossref","first-page":"11107","DOI":"10.2147\/DDDT.S560518","article-title":"Infusion-related reactions among cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-013 systematic review and meta-analysis","volume":"19","author":"Vitale","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.wneu.2026.125356_bib38","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.clnesp.2025.10.031","article-title":"Decreased appetite in cancer patients treated with immune checkpoint inhibitors (ICIs): the MOUSEION-012 systematic review and meta-analysis","volume":"70","author":"Vitale","year":"2025","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.wneu.2026.125356_bib39","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/neuros\/nyaa471","article-title":"Differences in genomic alterations between brain metastases and primary tumors","volume":"88","author":"Dono","year":"2021","journal-title":"Neurosurgery"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875026005723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875026005723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:20:24Z","timestamp":1794288024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875026005723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":39,"alternative-id":["S1878875026005723"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2026.125356","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-Treatment Performance Status and Prognosis in Patients with Brain Metastases as the First Manifestation of Advanced Nonsmall Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2026.125356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"125356"}}